ZBIO
NASDAQ HealthcareZenas BioPharma, Inc. - Common Stock
Biotechnology
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $28.24 |
|---|---|
| Volume | 874,474 |
| Market Cap | 1.78B |
| RSI (14-Day) | 63.6 |
| 200-Day MA | $25.30 |
| 50-Day MA | $21.49 |
| 52-Week High | $44.60 |
| 52-Week Low | $12.80 |
| Forward P/E | -12.47 |
| Price / Book | 6.35 |
๐ฏ Investment Strategy Scores
ZBIO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Over-Hyped (69/100) โ this strategy Overbought stocks (potential short candidates).
Lowest fit among scored strategies: ๐ Moon Shot (4/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ZBIO in your text
Paste any article, transcript, or post โ the tool will extract ZBIO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.